EHS
EHS

STAT Plus: Pharmalittle: Most drug price hikes occurred before Azar arrived; Novartis abandons antibiotics

Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short person has left for the local summer job and, as always, the official mascots are snoozing here and there. We, however, have no time to nap, since there is always much to be done. The world, after all, continues to spin no matter what. On that note, here are a few items of interest. Hope your day goes well and that you will reach out if anything interesting arises …

Novartis (NVS) is closing its antibiotic and antiviral research operations in the San Francisco Bay area and cutting about 140 jobs, the latest big drug maker to abandon this field. The company, which is not abandoning research into tropical diseases such as malaria, is looking to license its early-stage products and stressed that its Sandoz generics unit continues to manufacture and sell antibiotics and antivirals. The Access to Medicines Foundation noted that Novartis had 32 antimicrobial research and development projects in its pipeline.

Continue to STAT Plus to read the full story…

EHS
Back to top button